Thymosin Alpha-1 (TA1) is an immunomodulatory peptide built from a 28 amino acid sequence derived from prothymosin in the thymus. Its N-terminal acetylation drives bioactivity, and it carries a serum half-life of roughly two hours. The trade name is thymalfasin, also marketed as Zadaxin. It is approved in more than thirty-five countries for hepatitis B and C, while in the United States it remains investigational and off-label.

This lesson sits within the immune regulation track and covers what the literature describes for TA1: mechanism, the supporting evidence, and how clinicians frame its use across infectious, septic, and oncologic settings.

How it works

TA1 acts as a Toll-like receptor agonist, with primary activity at TLR-9 and TLR-2 on myeloid and dendritic cells, and engagement of additional receptors. It signals through MyD88-dependent and independent pathways, feeding into NF-kB, P38 MAPK, IRF7 interferon, and PI3K/AKT survival signaling. Dr. Seeds frames it less as a pure activator and more as a modulator of both innate and adaptive immunity.

On the cytokine side, it can increase interleukin-2, interleukin-10, interleukin-12, and interferon alpha and gamma, while modulating interleukin-1 beta and TNF-alpha downward. The net effect leans toward innate polarization and the Th1 arm, aiming to restore immune homeostasis. TA1 promotes thymic output, supports CD4 and CD8 maturation, can reduce exhaustion markers such as PD-1 and TIM-3, and contributes antioxidant and cytoprotective activity through glutathione and superoxide dismutase pathways.

Clinical evidence and application

Randomized controlled studies in hepatitis B reported improved virological and histological response at 1.6 mg subcutaneously twice weekly. A 2016 systematic review of nineteen trials in septic patients described a significant 28-day mortality reduction, and 2020 COVID-19 cohorts reported restored T-cell counts in severe disease. In non-small cell lung carcinoma, durations greater than twenty-four months were associated with better disease-free and overall survival in the reviewed data. Across trials, the safety profile was described as well tolerated with minimal adverse events.

Key clinical points

• TA1 is a 28 amino acid thymic peptide that acts as a Toll-like receptor modulator of innate and adaptive immunity, not FDA approved and used off-label in the US.
• Standard dosing referenced is 1.6 mg subcutaneous twice weekly, with daily or more frequent regimens described for sepsis and viral illness.
• The strongest evidence cited spans chronic hepatitis B, sepsis with immunoparalysis, and viral illness with lymphopenia.
• Suggested monitoring includes CBC with differential, CD4/CD8 counts, liver function tests, and CRP, reassessed at intervals based on the indication.
• Use caution in transplant patients on immunosuppressants and in autoimmune flares, and limit use in pregnancy and pediatrics given insufficient data.